Effects of treatment on endocrine function in patients with epilepsy

Current Treatment Options in Neurology

Volumn 7, Issue 4, 2005, Pages 273-280

  Pack, Alison ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; CLOMIFENE CITRATE; CLONAZEPAM; ETIRACETAM; FELBAMATE; FOLIC ACID; GABAPENTIN; GONADOTROPIN; LAMOTRIGINE; METFORMIN; MULTIVITAMIN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RISEDRONIC ACID; SALCATONIN; TESTOSTERONE; THYROID HORMONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; ZONISAMIDE;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ANDROGEN BLOOD LEVEL; ANOVULATION; ANTICONVULSANT THERAPY; BACKACHE; BODY WEIGHT DISORDER; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE MINERAL; BONE PAIN; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG ACTIVITY; DRUG CROSS REACTIVITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; EPILEPSY; EPISTAXIS; EUTHYROIDISM; FRACTURE; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; GYNECOLOGIC DISEASE; HEADACHE; HIRSUTISM; HUMAN; HYPERINSULINEMIA; MALE INFERTILITY; MENSTRUATION DISORDER; METRORRHAGIA; MUSCLE CRAMP; MYALGIA; NAUSEA; NEURAL TUBE DEFECT; NOSE IRRITATION; OLIGOMENORRHEA; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; REVIEW; SEXUAL DYSFUNCTION; SPERMATOZOON ABNORMALITY; SPERMATOZOON MOTILITY; STOMACH ULCER; TERATOGENICITY; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; VIRILIZATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 22544480299     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0037-8     Document Type: Review

References (35)

1. Gidal BE, Sheth RD, Magnus L, Herbeuval AF: Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003, 56:121-126.
2. Biton V, Mirza W, Montouris G, et al.: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001, 56:172-177.
3. Morrell MJ, Isojarvi J, Taylor AE, et al.: Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003, 54:189-199.
4. Morrell MJ, Flynn KL, Seale CG, et al.: Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001, 6:771-786.
5. Herzog AG, Coleman AE, Jacobs AR: Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol 2003, 54:625-637.
6. Rattya J, Pakarinen AJ, Knip M, et al.: Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001, 57:440-444.
7. Vainionpaa LK, Rattya J, Knip M, et al.: Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999, 45:444-450.
8. Morrell MJ, Giudice L, Flynn KL, et al.: Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002, 52:704-711.
9. Mikkonen K, Vainionpaa LK, Pakarinen AJ, et al.: Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004, 62:445-450.
10. Herzog AG, Drislane FW, Schomer DL, et al.: Differential effects of antiepileptic drugs on sexual function and reproductive hormones in men with epilepsy: interim analysis of a comparison between lamotrigine and enzyme-inducing antiepileptic drugs. Epilepsia 2004, 45:764-768.
11. Rattya J, Turkka J, Pakarinen AJ, et al.: Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001, 56:31-36.
12. Roste LS, Tauboll E, Morkrid L, et al.: Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol 2005, 12:118-124.
13. Bauer J, Blumenthal S, Reuber M, Stoffel-Wagner B: Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology 2004, 62:243-246.
14. Isojarvi JI, Lofgren E, Juntunen KS, et al.: Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 2004, 62:247-253.
15. Mikkonen K, Tapanainen P, Pakarinen AJ: Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 2004, 45:769-776.
16. Isojarvi JI, Turkka J, Pakarinen AJ, et al.: Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001, 42:930-934.
17. Vainionpaa LK, Mikkonen K, Rattya J, et al.: Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004, 45:197-203.
18. Souverein PC, Webb DJ, Petri H, et al.: Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005, 46:304-310.
19. Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
20. Farhat G, Yamout B, Mikati MA, et al.: Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
21. Andress DL, Ozuna J, Tirschwell D, et al.: Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
22. Ensrud KE, Walczak TS, Blackwell T, et al.: Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004, 62:2051-2057.
23. Pack AM, Olarte LS, Morrell MJ, et al.: Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003, 4:169-174.
24. Sato Y, Kondo I, Ishida S, et al.: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
25. Pack AM, Morrell MJ, Marcus R, et al.: Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005, 57:252-257.
26. Verrotti A, Greco R, Morgese G, et al.: Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000, 47:385-388.
27. Verotti A, Greco R, Latini G, et al.: Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002, 43:1488-1492.
28. Lord J, Wilkin T: Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol 2004, 16:481-486.
29. Drezner MK: Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004, 5(Suppl 2):S41-47.
30. Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
31. Chestnut III CH: Calcitonin in the prevention and treatment of osteoporosis. Osteoporos Int 1993, 3(Suppl 1):206-207.
32. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progesterone in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:366-368.
33. Harden CL, Pulver MC, Ravdin L, Javobs AR: The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999, 40:1402-1407.
34. Ettinger B, Black DM, Mitlak, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645.
35. Quattrocchi E, Kourlas H: Teriparatide: a review. Clin Ther 2004, 26:841-854.